Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | F2RL1 | P55085 | 3/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1632713 | 0.79 | PSEN1 (0.32) | — | |
| SCHEMBL1631909 | 0.77 | PSEN1 (0.48) | — | |
| SCHEMBL1632427 | 0.77 | CES2 (0.33) | CES2CES1 | |
| SCHEMBL1632141 | 0.77 | MEN1 (0.35) | CES2CES1CYP11B1CYP11B2 | |
| SCHEMBL1633953 | 0.68 | MEN1 (0.35) | CYP11B1CYP11B2 | |
| SCHEMBL1630845 | 0.68 | CES2 (0.42) | CES2CES1 | |
| SCHEMBL8270710 | 0.66 | ASPH (0.51) | — | |
| SCHEMBL1631329 | 0.65 | CES2 (0.39) | CES2CES1 | |
| SCHEMBL1631315 | 0.65 | CES2 (0.39) | CES2CES1F2RL1 | |
| SCHEMBL597127 | 0.64 | CES2 (0.38) | CES2CES1F2RL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932271-B2 | Heterocyclic methyl sulfone derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-7932271-B2 | Heterocyclic methyl sulfone derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-7932271-B2 | Heterocyclic methyl sulfone derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20060241302-A1 | Morpholine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-10-26 | — | — | US | disclosed |
| EP-1640366-A1 | HETEROCYCLIC METHYL SULFONE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241302-A1 | Morpholine derivatives | APP, BACE1, SMS | CES2 3381/4885CES1 2680/4885F2RL1 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.